Clinical Trials
2 trialsNCT04500548 2025-09-10
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01445379 2019-12-17
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed